
|Articles|October 19, 2009
Emerging Pharma Leadership Awards - Elizabeth Mutisya
Advertisement
Elizabeth Mutisya,
VP, US Medical Affairs, CMO,
Solvay Pharmaceuticals
Download Adobe Flash Player
“We need to do a better job of delineating the value our industry provides in addressing medical problems. Health economics allows us to better quantify the benefits of our solutions to patient outcomes, health-related quality of life, and individuals involved in patient care.” Listen to the Podcast for more coverage.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
5





